JP2024516542A5 - - Google Patents

Info

Publication number
JP2024516542A5
JP2024516542A5 JP2023561278A JP2023561278A JP2024516542A5 JP 2024516542 A5 JP2024516542 A5 JP 2024516542A5 JP 2023561278 A JP2023561278 A JP 2023561278A JP 2023561278 A JP2023561278 A JP 2023561278A JP 2024516542 A5 JP2024516542 A5 JP 2024516542A5
Authority
JP
Japan
Prior art keywords
peptide
cells
optionally
cell
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561278A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516542A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023714 external-priority patent/WO2022216856A1/en
Publication of JP2024516542A publication Critical patent/JP2024516542A/ja
Publication of JP2024516542A5 publication Critical patent/JP2024516542A5/ja
Pending legal-status Critical Current

Links

JP2023561278A 2021-04-06 2022-04-06 Mhcクラスiペプチドを含む方法および組成物 Pending JP2024516542A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171137P 2021-04-06 2021-04-06
US63/171,137 2021-04-06
PCT/US2022/023714 WO2022216856A1 (en) 2021-04-06 2022-04-06 Methods and compositions comprising mhc class i peptides

Publications (2)

Publication Number Publication Date
JP2024516542A JP2024516542A (ja) 2024-04-16
JP2024516542A5 true JP2024516542A5 (cg-RX-API-DMAC7.html) 2025-08-20

Family

ID=83546562

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561278A Pending JP2024516542A (ja) 2021-04-06 2022-04-06 Mhcクラスiペプチドを含む方法および組成物

Country Status (4)

Country Link
US (1) US20240218019A1 (cg-RX-API-DMAC7.html)
EP (1) EP4320145A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024516542A (cg-RX-API-DMAC7.html)
WO (1) WO2022216856A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240133853A (ko) * 2023-02-28 2024-09-05 루다큐어 주식회사 신규 펩타이드 및 이의 용도
CN117466987A (zh) * 2023-09-19 2024-01-30 暨南大学 一种TNF-α衍生多肽、纳米硒复合肽及制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029271A2 (en) * 2001-09-24 2003-04-10 Nuvelo Novel nucleic acids and polypeptides
US8361780B2 (en) * 2005-06-30 2013-01-29 University Of Georgia Research Foundation, Inc. Biological system and assay for identifying modulators of tubulin ligases
US8791233B2 (en) * 2011-05-24 2014-07-29 Northwestern University Maspin-based peptides and methods of use thereof
EP3075389A1 (en) * 2015-03-31 2016-10-05 Technische Universität München T cell receptors and peptides derived by mutations for the treatment of cancer
JP6913032B2 (ja) * 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
SG11201808196UA (en) * 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
WO2018213803A1 (en) * 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
BR112020000590A2 (pt) * 2017-07-12 2020-07-14 Nouscom Ag método de seleção de uma coleção, métodos para determinar as sequências de aminoácidos e para produzir uma cvp ou uma coleção de ácidos nucleicos, cvp, coleções de peptídeos de vacina, de ácidos nucleicos, de um ou mais vetores de expressão e coleção de vetores de expressão
KR20210040355A (ko) * 2018-06-19 2021-04-13 바이오엔테크 유에스 인크. 네오항원 및 이의 용도

Similar Documents

Publication Publication Date Title
EP3615565B1 (en) Tcr and peptides
US20240374728A1 (en) T Cell Modification
KR102048228B1 (ko) T 세포 자극용 엑소좀 및 이의 약제학적 용도
US10654907B2 (en) Methods and compositions for producing a cell expressing a T cell receptor
JP2023513605A5 (cg-RX-API-DMAC7.html)
Bettinotti et al. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy
JP2005528091A (ja) T細胞由来小胞の機能化、および免疫原性医薬組成物を製造するためのその使用
CN120943929B (zh) 靶向afp肽的t细胞受体、其制备方法及伴随诊断试剂盒
JP2024515646A5 (cg-RX-API-DMAC7.html)
CN120399034B (zh) 靶向prame肽的t细胞受体及其制备方法
US20240000834A1 (en) Ras mutant epitope peptide and t cell receptor recognizing ras mutant
JP2019536429A (ja) ポリオーマウイルスのための免疫療法
JP2025516264A (ja) 多重化t細胞受容体組成物、その併用療法、及び使用
JP2024526836A5 (cg-RX-API-DMAC7.html)
JP2024517630A5 (cg-RX-API-DMAC7.html)
JP2022554349A5 (cg-RX-API-DMAC7.html)
WO2024243807A1 (zh) 靶向ny-eso-1的高亲和力t细胞受体及其应用
HK40117446A (en) T cell modification
WO2026040998A1 (zh) Tp53突变体表位肽和特异性t细胞受体及其应用
WO2026018922A1 (ja) SARS-CoV-2感染症治療および/または予防用細胞及びその製法
JP2026500364A (ja) T細胞抗原受容体およびその調製方法並びに使用
CN120554482A (zh) 一种具有流感病毒血凝素蛋白特异性识别功能的γδT细胞受体及其应用
JP2024123281A (ja) SARS-CoV-2由来のT細胞エピトープペプチド
Wolf New Approaches to Understand T Cell Activation and Circumvent T Cell Dysfunction in Cancer
JP2022152704A (ja) HTLV-1がコードするTax抗原特異的細胞傷害性Tリンパ球のT細胞受容体又はその機能的断片